Minimize
 

RTOG 1102 Protocol Information

Minimize
A Phase I Study of Induction Ganitumab (IND #113278) and Gemcitabine, Followed by Ganitumab, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer
Principal Investigator: Christopher Crane, MD
Primary Objective:

To evaluate the maximum dose of ganitumab, up to a target dose of 20 mg/kg, given concurrently with capecitabine and radiation following induction ganitumab and gemcitabine for patients with locally advanced pancreatic cancer.

 

Patient Population:

Pathologically confirmed (histologic or cytologic), locally advanced adenocarcinoma of the pancreas.

Target Accrual: 42
Current Accrual: 8
Status: Terminated
Date: 11/5/2013
Participating Sites:
Boston Medical Center MBCCOP Boston MA
Bronson Battle Creek Battle Creek MI
Bryn Mawr Hospital Bryn Mawr PA
Christiana Care Health System-Christiana Hospital Newark DE
Emory University Hospital Midtown Atlanta GA
Emory University Hospital/Winship Cancer Institute Atlanta GA
Grand Rapids Clinical Oncology Program Grand Rapids MI
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore MD
Lankenau Medical Center Wynnewood PA
M D Anderson Cancer Center Houston TX
Mainline Health CCOP Wynnewood PA
Margaret R Pardee Memorial Hospital Hendersonville NC
Mercy Health Mercy Campus Muskegon MI
Mercy Health Saint Mary's Grand Rapids MI
North Main Radiation Oncology Providence RI
Northwestern University Chicago IL
Ohio State University Medical Center Columbus OH
Paoli Memorial Hospital Paoli PA
Reading Hospital Reading PA
Rhode Island Hospital Providence RI
Saint Joseph Hospital - Orange Orange CA
Spectrum Health at Butterworth Campus Grand Rapids MI
Summa Akron City Hospital/Cooper Cancer Center Akron OH
The James Graham Brown Cancer Center at University of Louisville Louisville KY
Thomas Jefferson University Hospital Philadelphia PA
University of Rochester Rochester NY
Updated: 11/6/2013

You must be logged in to view this file.

Login  |  Close

You must be logged in to view this file.

Login  |  Close